Role of MIF -173G/C and Mbl2 codon 54A/B variants in risk of multiple myeloma: An association study.

Pehlivan M., Nursal A., Gündeş İ., Oyacı Y., Kıvanç D., Pehlivan S.

Endocrine, metabolic & immune disorders drug targets, vol.21, pp.925-931, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21
  • Publication Date: 2021
  • Doi Number: 10.2174/1871530320999200818102731
  • Journal Name: Endocrine, metabolic & immune disorders drug targets
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
  • Page Numbers: pp.925-931
  • Keywords: Multiple myeloma, malignant disease, macrophage inhibitory factor, mannose binding lectin, variant, Turkish population, MIGRATION INHIBITORY FACTOR, MANNOSE-BINDING LECTIN, FACTOR GENE, PROMOTER POLYMORPHISMS, CANCER, LEUKEMIA, MIF, DIAGNOSIS, PATTERN, IMPACT
  • Istanbul University Affiliated: Yes

Abstract

Background: Multiple myeloma (MM) is a malignant disease manifested by the clonal proliferation of atypical plasma cells. Macrophage inhibitory factor (MIF) is one of the pleiotropic regulators in various biological and cellular processes. Mannose-binding lectin (MBL) is a crucial protein involved in the lectin pathway of the immune system.